Upsher-Smith Laboratories, Inc issued the following announcement on Aug. 2.
Upsher-Smith Laboratories, LLC (Upsher-Smith) todayannounced that it has added another product to its growing generic portfolio, supporting itscommitment to expanding and diversifying its product offerings. The Company has launchedfour new products and two line extensions this year.
Upsher-Smith’s Bexarotene Capsules, 75 mg, an AB-rated generic version of thebranded product, Targretin® (bexarotene) Capsules*, was approved by the U.S. Food and DrugAdministration (FDA) on July 25, 2018.
“This is an exciting time for Upsher-Smith. Our portfolio is more diversified than everbefore and we are optimistic that we will continue to grow given the record number of potentialANDA submissions planned over the next several years and key strategic partnerships we’veformed,” said Rusty Field, President and CEO, Upsher-Smith.
Original source can be found here.